US Oncology, the nation’s foremost cancer treatment and research network, has established US Oncology Clinical Development (USOCD), a full service contract research organization (CRO). USOCD formalizes many of the services that US Oncology Research has provided since its inception in 1999. For more than a decade US Oncology Research has offered pharmaceutical and biotechnology companies elements of the clinical trial management process.
Lees meer..

Rib-X Pharmaceuticals, Inc. (”Rib-X” or the “Company”), a development-stage company focused on the discovery and development of novel antibiotics for the treatment of antibiotic-resistant infections, announced that its lead compound, delafloxacin, has been selected by R&D Directions editors for the 8th annual report on “100 Great Investigational Drugs,” published in the March 2009 issue. R&D Directions is a leading pharmaceutical industry magazine.
Lees meer..

Xanodyne Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration (FDA) has accepted for filing and granted priority review status for its investigational proprietary formulation of tranexamic acid for the treatment of women with menorrhagia, heavy menstrual bleeding (HMB), and its accompanying symptoms.
Lees meer..

Patients and health services are getting a poor return on their investment into new drugs, say experts in an article published on bmj.com today. Industry makes much of the expense of bringing a new drug to market, yet the public provides most of the support for developing and evaluating new drugs, write Silvio Garattini and Iain Chalmers.
Lees meer..

With just a few hours left in the 2009 General Assembly session, Georgia lawmakers began considering a new wrinkle in a state economic stimulus bill.

Lees meer..

Shire Pharmaceuticals Group PLC wants to invest its resources on buying small drug companies and striking licensing deals, rather than manufacturing, spokesman Matt Cabrey said.

Lees meer..

Synergetics USA Inc. signed a new, three-year marketing agreement this week with Codman & Shurtleff Inc., an affiliate of Johnson & Johnson (NYSE: JNJ). (JNJ)

Lees meer..

Artsen positief over HPV-vaccin
Lees meer..

Kraak EPD-pas kost Rijk miljoenen euro’s
Lees meer..

Kwart krijgt huidkanker
Lees meer..